Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

49.66USD
21 Feb 2018
Change (% chg)

$1.04 (+2.14%)
Prev Close
$48.62
Open
$48.89
Day's High
$50.88
Day's Low
$48.89
Volume
75,115
Avg. Vol
114,785
52-wk High
$51.25
52-wk Low
$27.94

Select another date:

Mon, Jan 8 2018

BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million

* EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Emergent Biosolutions reports third quarter results

* Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance

BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector

* Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 million to supply nerve agent antidote auto-injector

BRIEF-Emergent Biosolutions completes acquisition of Raxibacumab from GSK​

* Emergent Biosolutions Inc - ‍transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017​

BRIEF-Emergent BioSolutions signs five-year follow-on contract with DoD valued at up to $171 mln​

* Emergent BioSolutions to supply DoD with chemical threat countermeasure RSDL under five-year follow-on contract valued at up to $171 million

BRIEF-Emergent BioSolutions awarded $63 mln BARDA contract to develop treatment for cyanide exposure

* Emergent BioSolutions - awarded contract valued at about $63 mln by Biomedical Advanced Research And Development Authority

Select another date: